Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia 2010 Feb;24(2):355-70 PMID: 20016527 PMCID: PMC4300959

Pubmed ID





From 1984 to 2001, the Pediatric Oncology Group (POG) conducted 12 acute lymphoblastic leukemia (ALL) studies. Ten-year event-free survival (EFS) for patients >12 months of age with B-precursor ALL on acute leukemia in children 14, 15 and 16 series were 66.7+/-1.2%, 68.1+/-1.4% and 73.2+/-2.1%, respectively. Intermediate dose methotrexate (ID MTX; 1 g/m(2)) improved outcomes for standard risk patients (10-year EFS 77.5+/-2.7% vs 66.3+/-3.1% for oral MTX). Neither MTX intensification (2.5 g/m(2)) nor addition of cytosine arabinoside/daunomycin/teniposide improved outcomes for higher risk patients. Intermediate dose mercaptopurine (1 g/m(2)) failed to improve outcomes for either group. Ten-year EFS for patients with T-cell ALL, POG 8704 and 9404 were 49.1+/-3.1% and 72.2+/-4.7%, respectively. Intensive asparaginase (10-year EFS 61.8 vs 42.7%) and high-dose MTX (5 g/m(2)) (10-year EFS 78.0 vs 65.8%) improved outcomes. There was a non-significant improvement in EFS for infants (10-year EFS 17.7+/-7.2-31.9+/-8.3%). Prognostic indicators for B-precursor ALL were age and WBC at diagnosis, gender, central nervous system disease, DNA index and cytogenetic abnormalities. Only gender was prognostic in T-cell ALL. In infants, WBC and MLL translocation were linked to inferior outcome.

Author List

Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, Camitta BA


Bruce M. Camitta MD Clinical Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Antineoplastic Combined Chemotherapy Protocols
Child, Preschool
Chromosome Aberrations
Combined Modality Therapy
Cranial Irradiation
Follow-Up Studies
Neoplasm Recurrence, Local
Neoplasm, Residual
Neoplasms, Second Primary
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Remission Induction
Risk Factors
Survival Rate
Time Factors
Treatment Outcome
Young Adult
jenkins-FCD Prod-353 9ccd8489072cb19f5b9f808bb23ed672c582f41e